RAS-mutant Colorectal Cancer
2 clinical trials · Condition
◉ Watch RAS-mutant Colorectal Cancer
| Record | Firm | Date |
|---|---|---|
| SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. (NCT06835179) | The First Affiliated Hospital with Nanjing Medical University | 2025-02-01 |
| Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation (NCT03271047) | Pfizer | 2017-10-18 |
Track RAS-mutant Colorectal Cancer automatically
Every clearance here is in the API, with alerts when new ones post.